Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given an average rating of “Hold” by the ten analysts that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $8.1429.

Several equities analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their price target for the stock from $4.00 to $7.00 in a report on Monday, December 1st. Guggenheim raised Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Monday, October 27th. Stifel Nicolaus raised their target price on Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Finally, Mizuho set a $6.00 price target on shares of Neumora Therapeutics in a report on Monday, January 5th.

Neumora Therapeutics Price Performance

NMRA opened at $2.22 on Monday. Neumora Therapeutics has a 1 year low of $0.61 and a 1 year high of $3.25. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85. The company has a market capitalization of $370.94 million, a price-to-earnings ratio of -1.51 and a beta of 3.22. The firm’s fifty day moving average price is $2.20 and its two-hundred day moving average price is $1.88.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). As a group, analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Neumora Therapeutics

In related news, Director Kristina Burow bought 1,915,700 shares of Neumora Therapeutics stock in a transaction dated Monday, October 27th. The stock was purchased at an average cost of $2.61 per share, with a total value of $4,999,977.00. Following the transaction, the director directly owned 6,046,907 shares of the company’s stock, valued at approximately $15,782,427.27. The trade was a 46.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Arch Venture Partners Xii, Llc purchased 1,915,700 shares of the firm’s stock in a transaction dated Monday, October 27th. The shares were bought at an average price of $2.61 per share, with a total value of $4,999,977.00. Following the purchase, the insider owned 6,046,907 shares in the company, valued at $15,782,427.27. The trade was a 46.37% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 26.80% of the company’s stock.

Institutional Trading of Neumora Therapeutics

Hedge funds have recently made changes to their positions in the company. Legacy Private Trust Co. grew its stake in shares of Neumora Therapeutics by 35.7% during the 4th quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock worth $34,000 after acquiring an additional 5,000 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in Neumora Therapeutics in the 3rd quarter valued at about $1,512,000. Public Employees Retirement System of Ohio purchased a new stake in Neumora Therapeutics during the third quarter valued at about $44,000. Millennium Management LLC boosted its position in Neumora Therapeutics by 63.1% during the third quarter. Millennium Management LLC now owns 2,008,248 shares of the company’s stock worth $3,655,000 after purchasing an additional 776,856 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Neumora Therapeutics by 92.5% in the third quarter. Bank of America Corp DE now owns 137,429 shares of the company’s stock worth $250,000 after purchasing an additional 66,049 shares in the last quarter. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.